Back
ESC Premium Access

Prompt initiation of agalsidase alfa therapy is associated with improved cardiovascular outcomes in the Fabry Outcome Survey

Session: Cardiomyopathy in Fabry disease
Topic: Cardiomyopathies
Speaker: Professor A. Linhart (Prague, CZ)
Event: ESC Congress 2017

Congress Presentation

Add to my library

Like

About the speaker

Professor Ales Linhart

First Faculty of Medicine and General Teaching Hospital, Prague (Czechia)
30 presentations
0 follower

6 more presentations in this session

Comprehensive cardiovascular magnetic resonance assessment of anderson-fabry cardiomyopathy- natural history and assessment of treatment effect

Speaker: Doctor A. Reid (Manchester, GB)

Access
Abstract
Slides
Like
Thumbnail

Treatment of Fabry disease with a new oral drug: Initial real-world single-center experience

Speaker: Mr J. Muentze (Wuerzburg, DE)

Access
Abstract
Like
Thumbnail

Efficacy of enzyme replacement therapy in Fabry disease with advanced organ involvement

Speaker: Doctor P. Nordbeck (Wuerzburg, DE)

Access
Abstract
Like
Thumbnail

Long-term benefit of enzyme replacement therapy on cardiac manifestation in Japanese Fabry disease

Speaker: Doctor I. Anan (Tokyo, JP)

Access
Abstract
Slides
Like
Thumbnail

Role of serum biomarkers for monitoring disease progression in the cardio-specific alpha-galactosidase A genotype N215S

Speaker: Mr D. Oder (Würzburg, DE)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Cardiomyopathy in Fabry disease

Speakers: Professor A. Linhart, Doctor A. Reid, Mr J. Muentze, Doctor P. Nordbeck, Doctor I. Anan...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources